NCT07211932View on ClinicalTrials.gov

Tofacitinib in Juvenile Idiopathic Arthritis

Not yet recruitingOBSERVATIONAL
Enrollment

58

Participants

Timeline

Start Date

December 31, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Juvenile Idiopathic Arthritis (JIA)
Interventions
DRUG

Tofacitinib

Patients received tofacitinib for the treatment of juvenile idiopathic arthritis (JIA).

Trial Locations (3)

Unknown

Hospital Sant Joan de Déu Barcelona, Barcelona

Corporació Sanitària Parc Taulí de Sabadell, Sabadell

08720

Hospital de Vilafranca, Vilafranca del Penedès

All Listed Sponsors
lead

Consorci Sanitari de l'Alt Penedès i Garraf

OTHER

NCT07211932 - Tofacitinib in Juvenile Idiopathic Arthritis | Biotech Hunter | Biotech Hunter